Repeated hepatocyte growth factor neutralizing antibody treatment leads to HGF/SF unresponsiveness in human glioblastoma multiforme cells

Cancer Letters

Volumn 291, Issue 2, 2010, Pages 209-216

  Zhao, Ping ^a,b   Gao, Chongfeng ^b   Dykema, Karl ^b   Furge, Kyle ^b   Feng, Zhenqing ^a   Cao, Brian ^a,b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

Glioblastoma multiforme; Heparin; HGF; Neutralizing antibody; Xenograft

Indexed keywords

CASPASE 8; HEPARIN; INTERLEUKIN 8; NEUTRALIZING ANTIBODY; SCATTER FACTOR; SCATTER FACTOR NEUTRALIZING ANTIBODY; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR XENOGRAFT;

3T3 CELLS; ANIMALS; ANTIBODIES, NEUTRALIZING; BLOTTING, WESTERN; CELL DIVISION; CELL LINE, TUMOR; DOGS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HEPARIN; HEPATOCYTE GROWTH FACTOR; HUMANS; KIDNEY; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; TRANSPLANTATION, HETEROLOGOUS;

MUS MUSCULUS;

EID: 77950019417     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.10.014     Document Type: Article

References (23)

1. Trusolino L., and Comoglio P.M. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat. Rev. Cancer 2 4 (2002) 289-300
2. Birchmeier C., Birchmeier W., Gherardi E., and Vande Woude G.F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 4 12 (2003) 915-925
3. Bottaro D.P., Rubin J.S., Faletto D.L., Chan A.M., Kmiecik T.E., Vande Woude G.F., and Aaronson S.A. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251 (1991) 802-804
4. Rubin J.S., Bottaro D.P., and Aaronson S.A. Hepatocyte growth factor/scatter factor and its receptor, the c-met proto-oncogene product. Biochem. Biophys. Acta 1155 (1993) 357-371
5. Tsarfaty I., Rong S., Resau J.H., Shen R., Pedro Pinto D.S., and Vande Woude G.F. The met proto-oncogene in mesenchymal to epithelial cell conversion. Science 263 (1994) 98-101
6. Montesano R., Matsumoto K., Nakamura T., and Orci L. Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell 67 (1991) 901-908
7. Tsarfaty I., Resau J.H., Rulong S., Keydar I., Faletto D.L., and Vande Woude G.F. The met proto-oncogene receptor and lumen formation. Science 257 (1992) 1258-1261
8. Okada M., Matsumori A., Ono K., Miyamoto T., Takahashi M., and Sasayama S. Hepatocyte growth factor is a major mediator in heparin-induced angiogenesis. Biochem. Biophys. Res. Commun. 255 (1999) 80-87
9. Schmidt N., Westphal M., Hagel C., Ergun S., Stavrou D., Rosen E., and Lamszus K. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int. J. Cancer 84 (1999) 10-18
10. Koochekpour S., Jeffers M., Rulong S., Taylor G., Klineberg E., Hudson E.A., Resau J.H., and Vande Woude G.F. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res. 57 (1997) 5391-5398
11. Laterra J., Nam M., Rosen E., Rao J.S., Lamszus K., Goldberg I.D., and Johnston P. Scatter factor/hepatocyte growth factor gene transfer enhances glioma growth and angiogenesis in vivo. Lab Invest. 76 4 (1997) 565-577
12. Cao B., Su Y., Oskarsson M., Zhao P., Kort E., Fisher R.J., Wang L.M., and Vande Woude G.F. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc. Natl. Acad. Sci. USA 98 (2001) 7443-7448
13. Prandoni P., Falanga A., and Piccioli A. Cancer and venous thromboembolism. Lancet Oncol. 6 (2005) 401-410
14. Sideras K., Schaefer P.L., Okuno S.H., et al. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin. Proc. 81 6 (2006) 758-767
15. Sakata H., Stahl S.J., Taylor W.G., Rosenberg J.M., Sakaguchi K., Wingfield P.T., and Rubin J.S. Heparin binding and oligomerization of hepatocyte growth factor/scatter factor isoforms. J. Biol. Chem. 272 (1997) 9457-9463
16. Rong S., Oskarsson M., Faletto D., et al. Tumorigenesis induced by coexpression of human hepatocyte growth factor and the human Met protooncogene leads to high levels of expression of the ligand and receptor. Cell Growth Differ. 4 (1993) 563-569
17. Jeffers M., Rong S., and Vande Woude G.F. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signaling in human cells concomitant with induction of the urokinase proteolysis network. Mol. Cell Biol. 16 (1996) 1115-1125
18. Liang Y., Diehn M., Watson N., Bollen A.W., Aldape K.D., Nicholas M.K., Lamborn K.R., Berger M.S., Botstein D., Brown P.O., and Israel M.A. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc. Natl. Acad. Sci. USA 102 16 (2005) 5814-5819
19. Buie L.W., and Valgus J. Bevacizumab: a treatment option for recurrent glioblastoma multiforme. Ann. Pharmacother. 42 10 (2008) 1486-1490
20. Waugh D.J., and Wilson C. The interleukin-8 pathway in cancer. Clin. Cancer Res. 14 (2008) 6735-6741
21. Huang S., Mills L., Mian B., et al. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am. J. Pathol. 161 (2002) 125-134
22. Mian B., Dinney C., Bermejo C., et al. Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-κB. Clin. Cancer Res. 9 (2003) 3167-3175
23. Ren Y., Cao B., Law S., et al. Hepatocyte growth factor promotes cancer cell migration and angiogenic factors expression: a prognostic marker of human esophageal squamous cell carcinomas. Clin. Cancer Res. 11 (2005) 6190-6197